123
Participants
Start Date
April 30, 2009
Primary Completion Date
November 30, 2015
Study Completion Date
June 15, 2019
erlotinib hydrochloride
oral administration
gemcitabine hydrochloride
Intravenous administration
therapeutic conventional surgery
NYU Cancer Institute at New York University Medical Center, New York
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore
St. Agnes Hospital Cancer Center, Baltimore
Surgical Oncology Associates, Newport News
Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg
Lakeland Regional Cancer Center at Lakeland Regional Medical Center, Lakeland
University of Mississippi Cancer Clinic, Jackson
David L. Rike Cancer Center at Miami Valley Hospital, Dayton
Samaritan North Cancer Care Center, Dayton
CCOP - Dayton, Dayton
Charles F. Kettering Memorial Hospital, Kettering
St. Francis Hospital Cancer Care Services, Indianapolis
Methodist Estabrook Cancer Center, Omaha
Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa
Kaiser Permanente Medical Center - Los Angeles, Los Angeles
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange
Rebecca and John Moores UCSD Cancer Center, La Jolla
St. Vincent's Medical Center, Bridgeport
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
UVMC Cancer Care Center at Upper Valley Medical Center, Troy
Providence Cancer Center at Providence Portland Medical Center, Portland
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison
Princess Margaret Hospital, Toronto
Collaborators (2)
National Cancer Institute (NCI)
NIH
OSI Pharmaceuticals
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Alliance for Clinical Trials in Oncology
OTHER